previou
studi
demonstr
glycopeptid
compound
carri
hydrophob
substitu
favor
pharmacolog
ie
antibacteri
antivir
properti
report
vitro
antiinfluenza
viru
activ
aglycoristocetin
deriv
contain
hydrophob
side
chainsubstitut
cyclobutenedion
lead
compound
display
antivir
effect
concentr
consist
amongst
influenza
b
virus
select
index
structur
analogu
deriv
aglycovancomycin
found
inact
hydrophob
side
chain
shown
import
determin
activ
narrow
structureact
relationship
broad
activ
sever
human
influenza
virus
suggest
highli
conserv
interact
site
presum
relat
influenza
viru
entri
process
compound
prove
inact
sever
unrel
rna
dna
virus
except
varicellazost
viru
favor
activ
note
elsevi
bv
right
reserv
current
avail
drug
treatment
influenza
viru
infect
compris
ion
channel
blocker
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
de
clercq
moscona
stockpil
oseltamivir
lesser
extent
zanamivir
advoc
context
pandem
prepared
et
al
yet
recent
isol
oseltamivirresist
season
influenza
viru
mutant
even
untreat
patient
warrant
continu
caution
lackenbi
et
al
van
der
vri
et
al
addit
antiinfluenza
viru
compound
urgent
develop
novel
antivir
target
highli
conserv
amongst
influenza
viru
sub
type
henc
less
prone
genet
variat
resist
select
one
attract
therapeut
strategi
would
blockad
viral
entri
host
cell
cellular
entri
process
influenza
virus
unravel
sinc
mani
year
review
skehel
wiley
key
role
play
viral
envelop
glycoprotein
hemagglutinin
ha
contain
receptorbind
site
initi
attach
sialyl
cellular
receptor
govern
receptor
specif
human
versu
avian
influenza
viru
subtyp
chandrasekaran
et
al
nichol
et
al
addit
cellular
uptak
viru
endocytosi
ha
mediat
low
phinduc
fusion
viral
envelop
endosom
membran
lead
releas
viral
ribonucleoprotein
cytosol
although
ha
extens
studi
biochem
epidemiolog
perspect
specif
antivir
drug
block
hareceptor
interact
remain
clinic
develop
sever
report
avail
vitro
activ
smallmolecul
inhibitor
influenza
viru
fusion
act
prevent
conform
chang
ha
low
ph
deshpand
et
al
plotch
et
al
unfortun
develop
slow
due
inferior
activ
human
influenza
viru
sub
type
rapid
select
resist
andor
unsatisfactori
outcom
anim
model
yagi
et
al
glycopeptid
compound
repres
larg
seri
natur
semisynthet
fulli
synthet
compound
wide
recogn
potent
activ
gramposit
bacteria
nicola
et
al
sever
studi
demon
strate
hydrophob
deriv
glycopeptid
antibiot
eg
vancomycin
eremomycin
andor
aglycon
exert
antibacteri
activ
glycopeptideresist
enterococci
cooper
et
al
printsevskaya
et
al
pace
yang
remark
lipophil
glycopeptid
compound
found
inhibitori
activ
coronavirus
hiv
latter
ascrib
inhibit
hiv
entri
process
balzarini
et
al
balzarini
et
al
preobrazhenskaya
olsufyeva
report
chemic
synthesi
antiinfluenza
viru
activ
structureact
relationship
novel
glycopeptid
compound
carri
hydrophob
side
chain
aglycoristocetin
backbon
fig
highyield
synthesi
aglycovancomycin
aglycoristocetin
fig
perform
origin
describ
wanner
et
al
consist
deglycosid
parent
antibiot
hydrogen
fluorid
anisol
neutral
ph
fig
sztaricskai
et
al
aglycon
convert
squaric
acid
amid
ester
coupl
dimethyl
squarat
follow
reaction
primari
amin
yield
correspond
asymmetr
squaric
diamid
use
regioselect
procedur
without
requir
protect
group
strategi
tietz
et
al
sztaricskai
et
al
primari
amin
acid
triglycin
dopamin
n
piperidin
base
observ
compound
display
favor
antiinfluenza
viru
activ
see
subsequ
modif
perform
studi
impact
increas
steric
bulk
rigid
aromat
side
chain
prepar
shown
introduct
hydrophob
substitu
glycopeptid
antibiot
enhanc
activ
glycopeptideresist
bacteria
cooper
et
al
printsevskaya
et
al
pace
yang
unfortun
product
lower
watersolubl
improv
solubl
squaric
acid
amid
ester
react
sztaricskai
et
al
dglucosamin
dgalactosamin
result
asymmetr
squaric
diamid
respect
product
carbohydr
moieti
link
aglycon
unusu
manner
ie
cyclobutandion
moieti
directli
one
hydroxyl
group
parent
glycopeptid
antibiot
structur
reaction
yield
physicochem
data
aglycon
squaric
acid
amid
ester
correspond
asymmetr
diamid
summar
tabl
homogen
compound
check
tlc
hplc
structur
confirm
mass
spectrometri
first
convert
squaric
acid
amid
ester
respect
follow
convers
asymmetr
squaric
diamid
respect
see
tabl
structur
group
present
primari
amin
final
product
squaric
acid
amid
ester
respect
convert
asymmetr
squaric
diamid
deriv
aglycovancomycin
deriv
aglycoristocetin
b
hplc
condit
instrument
water
detect
column
lichrosph
mm
mm
inject
volum
l
correspond
g
compound
solvent
tabl
sever
asymmetr
squaric
diamid
deriv
aglycoristocetin
exert
mark
activ
influenza
viru
potent
compound
phenylbenzyl
deriv
averag
antivir
ec
select
index
si
defin
ratio
mcc
ec
hexanol
deriv
ec
si
naphthyl
deriv
ec
si
activ
higher
squaric
acid
amid
ester
aglycoristocetin
ec
si
intermedi
activ
ec
observ
triglycyl
deriv
surprisingli
compar
activ
unsubstitut
aglycoristocetin
deriv
dgalactosamin
deriv
activ
two
three
influenza
viru
strain
test
deriv
contain
carboxypentyl
dglucosamin
substitu
activ
one
viru
strain
compound
carri
terphenyl
anthracen
substitu
complet
inact
thu
intrins
antiinfluenza
viru
activ
aglycoristocetin
markedli
increas
squaric
acid
amid
coupl
addit
hydrophob
side
chain
phenylbenzyl
group
optim
substitu
favor
effect
side
chain
appear
depend
differ
factor
name
neutral
charg
alcohol
aliphat
deriv
clearli
activ
correspond
carboxypentyl
compound
steric
bulki
activ
bulki
compound
aglycoristocetin
backbon
structur
shown
critic
inhibit
influenza
viru
sinc
activ
observ
compound
repres
aglycovancomycin
analogu
aglycoristocetin
aglycovancomycin
contain
central
heptapeptid
core
nonproteinogen
phenol
amino
acid
ie
c
e
unit
b
unit
unit
fig
main
structur
differ
glycopeptid
aglycon
follow
fig
wherea
aglycovancomycin
five
aromat
ring
ae
two
known
amino
acid
laspart
acid
nmethyldleucin
aglycoristocetin
seven
aromat
moi
tabl
cytotox
select
aglycoristocetin
deriv
human
anim
cell
line
cytotox
concentr
human
embryon
lung
hel
fibroblast
human
cervix
epitheli
hela
african
green
monkey
kidney
vero
crandel
felin
kidney
crfk
cell
nd
done
b
cytotox
concentr
defin
minimum
cytotox
concentr
mcc
cytotox
concentr
cf
legend
tabl
eti
ag
ii
addit
f
g
ring
aglycoristocetin
interconnect
via
diphenyleth
linkag
constitut
ristomycin
acid
moieti
iii
aglycoristocetin
lack
chloro
substitu
c
e
ring
present
aglycovancomycin
iv
ctermin
carboxyl
function
free
aglycovancomycin
contain
methyl
ester
aglycoristocetin
v
aglycoristocetin
primari
amin
function
wherea
aglycovancomycin
contain
secondari
amin
group
crowley
et
al
present
specul
structur
compon
explain
antivir
specif
aglycoristocetin
deriv
basic
test
panel
influenza
virus
contain
one
chimer
viru
subtyp
one
viru
one
b
viru
strain
tabl
lead
compound
evalu
activ
strain
apuerto
antivir
ec
valu
rang
b
strain
determin
cytostat
activ
mdck
cell
use
cell
count
assay
reveal
ic
valu
thu
emerg
potent
inhibitor
influenza
viru
replic
broad
activ
differ
sub
type
favor
select
glycopeptid
compound
evalu
activ
virus
besid
influenza
viru
none
follow
rna
virus
found
significantli
inhibit
glycopeptid
evalu
cpe
plaqu
reduct
assay
felin
coronaviru
examin
crandellre
felin
kidney
cell
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
perform
human
epitheli
hela
cell
viru
sindbi
viru
punta
toro
viru
test
african
green
monkey
vero
cell
human
embryon
lung
fibroblast
cell
infect
variou
dna
virus
glycopeptid
display
activ
compound
antivir
ec
valu
herp
simplex
viru
type
wildtyp
thymidin
kinasedefici
herp
simplex
viru
type
cytomegaloviru
vaccinia
viru
select
index
note
found
highli
activ
varicellazost
viru
vzv
wildtyp
thymidin
kinasedefici
antivir
ec
valu
select
index
divers
antivir
assay
perform
human
anim
cell
line
permit
obtain
detail
insight
cytotox
aglycoristocetin
deriv
select
influenza
viru
experi
tabl
compound
either
minim
cytotox
concentr
cytotox
valu
lead
compound
rang
previous
obtain
mdck
cell
glycopeptid
studi
previous
evalu
antibacteri
activ
sztaricskai
et
al
emerg
highli
activ
compound
present
antiinfluenza
viru
data
thu
agre
view
hydrophob
substitut
posit
impact
pharmacolog
ie
antibacteri
antivir
activ
glycopeptid
compound
printsevskaya
et
al
balzarini
et
al
balzarini
et
al
regard
antivir
mode
action
timeofaddit
studi
suggest
block
viral
entri
process
sinc
optim
antiinfluenza
viru
activ
obtain
compound
ad
mdck
cell
min
prior
simultan
viru
infect
detail
analysi
current
ongo
determin
effect
virusreceptor
interact
ie
bind
viral
ha
sialic
acid
terminu
cell
surfac
glycan
endocytosi
membran
fusion
ie
fusion
viral
envelop
endosom
membran
whatev
precis
mode
action
subtypeindepend
activ
provid
strong
support
interact
site
highli
conserv
amongst
human
influenza
viru
strain
consist
observ
influenza
viru
fulli
retain
sensit
eleven
sequenti
viru
passag
mdck
cell
presenc
concentr
within
human
influenza
viru
ha
sequenc
residu
fulli
conserv
particular
receptorbind
site
fusion
peptid
skehel
wiley
aglycoristocetin
compound
describ
repres
lead
compound
first
glycopeptid
report
activ
influenza
viru
narus
et
al
report
isol
character
antiinfluenza
viru
activ
two
kistamicin
antibiot
narus
et
al
similarli
compound
kistamicin
show
strong
activ
influenza
viru
low
activ
herp
simplex
viru
type
kistamicin
report
inact
hiv
syncytium
assay
narus
et
al
observ
antiinfluenza
viru
activ
kistamicin
higher
lipophil
substitu
present
termin
amin
function
reminisc
find
aglycoristocetin
deriv
conclus
broad
robust
antiinfluenza
viru
activ
aglycoristocetin
deriv
describ
studi
creat
new
avenu
develop
antiinfluenza
viru
agent
novel
mode
action
rel
narrow
structureact
relationship
point
highli
specif
interact
antivir
target
probabl
relat
interact
influenza
viru
hemagglutinin
cellular
receptor
studi
unravel
structureact
relationship
precis
mode
action
underway
laboratori
